aTyr Pharma (NASDAQ:LIFE) Stock Passes Above 200-Day Moving Average of $1.54

aTyr Pharma, Inc. (NASDAQ:LIFE)’s share price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.54 and traded as high as $1.65. aTyr Pharma shares last traded at $1.60, with a volume of 288,049 shares changing hands.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on LIFE shares. HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of aTyr Pharma in a research report on Friday, March 15th. Royal Bank of Canada decreased their price objective on shares of aTyr Pharma from $19.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, March 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $23.67.

aTyr Pharma Trading Down 1.2 %

The stock has a 50 day simple moving average of $1.82 and a 200-day simple moving average of $1.54. The company has a current ratio of 6.27, a quick ratio of 6.27 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $108.70 million, a P/E ratio of -1.67 and a beta of 1.25.

aTyr Pharma (NASDAQ:LIFE) last announced its earnings results on Thursday, March 14th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.02). On average, equities research analysts forecast that aTyr Pharma, Inc. will post -0.97 EPS for the current fiscal year.

Institutional Investors Weigh In On aTyr Pharma

A number of hedge funds have recently modified their holdings of the business. FMR LLC lifted its position in aTyr Pharma by 5.1% during the third quarter. FMR LLC now owns 8,556,925 shares of the biotechnology company’s stock valued at $13,520,000 after purchasing an additional 413,162 shares in the last quarter. Pale Fire Capital SE purchased a new position in shares of aTyr Pharma during the 3rd quarter valued at about $88,000. Granite Bay Wealth Management LLC purchased a new stake in aTyr Pharma in the 4th quarter worth approximately $25,000. Finally, Kingswood Wealth Advisors LLC bought a new stake in aTyr Pharma during the 1st quarter worth approximately $117,000. Institutional investors own 61.72% of the company’s stock.

aTyr Pharma Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.